View Document Preview and Link Document Date: 2015-06-02 03:59:18 Open Document File Size: 576,49 KB Share Result on Facebook
City EPALINGES / Copenhagen / / Company Sunstone Capital / Novartis Healthcare A/S / ALK Abello A/S / CRO Medicon A/S / Ablynx NV / Anergis SA / WJFS Inc. / Novo Nordisk A/S / / Country Switzerland / / Currency CHF / / Event FDA Phase / Employment Change / Funding / / Facility Copenhagen University / / IndustryTerm therapy of allergies / biopharmaceutical / pharmaceutical / allergy treatment / project management / biopharmaceutical industry / / MedicalCondition ragweed pollen allergy / allergic reaction / Allergies / novel / proprietary allergy / disease / pollen allergies / house dust mite allergy / birch pollen allergy / ultra-fast allergy / several novel COP allergy / allergy / cardiovascular and pulmonary diseases / prevalent and fastest growing chronic conditions / hypersensitivity / anaphylactic reactions / proprietary ultra-fast allergy / additional allergy / / MedicalTreatment immunotherapy / / Organization Copenhagen University / / Person Kim Simonsen / Vincent Charlon / / Position Chief Development Officer / Chief Operations Officer / Chief Executive Officer / Medical Director / Executive / Director of Clinical Operations / Director / Global Clinical Development / / Product Anergis / / Technology immunotherapeutics / antibodies / drug development / / SocialTag 
Anergis Appoints Kim Simonsen as Chief Development Officer − Senior Biotech Executive brings over 25 years of drug development expertise EPALINGES, Switzerland, June 2, 2015 – Anergis, a company developing novel and